Wellington Management Group LLP Grows Position in Humacyte, Inc. (NASDAQ:HUMA)

Wellington Management Group LLP raised its position in shares of Humacyte, Inc. (NASDAQ:HUMA) by 30.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 254,411 shares of the company’s stock after acquiring an additional 60,087 shares during the period. Wellington Management Group LLP owned approximately 0.21% of Humacyte worth $1,384,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Renaissance Technologies LLC grew its position in Humacyte by 693.0% in the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after acquiring an additional 524,600 shares in the last quarter. Thrivent Financial for Lutherans purchased a new position in shares of Humacyte in the 3rd quarter worth approximately $712,000. Millennium Management LLC boosted its holdings in shares of Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after purchasing an additional 1,334,641 shares during the period. Bank of New York Mellon Corp increased its position in shares of Humacyte by 62.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company’s stock valued at $1,219,000 after purchasing an additional 97,931 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in Humacyte by 1,018.4% during the 2nd quarter. AQR Capital Management LLC now owns 256,342 shares of the company’s stock valued at $1,230,000 after buying an additional 233,422 shares during the period. 44.71% of the stock is currently owned by institutional investors.

Insider Activity at Humacyte

In other Humacyte news, Director Brady W. Dougan sold 427,459 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the sale, the director now owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Laura E. Niklason sold 811,172 shares of Humacyte stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.44, for a total value of $3,601,603.68. Following the completion of the transaction, the chief executive officer now owns 2,419,712 shares in the company, valued at $10,743,521.28. This represents a 25.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,500,000 shares of company stock worth $6,606,799 over the last three months. 11.20% of the stock is owned by corporate insiders.

Humacyte Trading Down 2.3 %

Shares of NASDAQ HUMA opened at $3.46 on Friday. Humacyte, Inc. has a twelve month low of $2.48 and a twelve month high of $9.97. The firm has a market cap of $435.47 million, a PE ratio of -2.58 and a beta of 1.38. The business has a fifty day simple moving average of $4.85 and a two-hundred day simple moving average of $5.87. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61.

Analysts Set New Price Targets

Several brokerages have recently weighed in on HUMA. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the company a “neutral” rating in a research note on Friday, October 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a research report on Friday, September 20th. Benchmark restated a “buy” rating and set a $15.00 target price on shares of Humacyte in a research report on Thursday, October 10th. BTIG Research reiterated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Finally, EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a report on Monday, September 9th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $13.00.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.